PT-141 for women: who it's approved for and what to expect

What the approval actually covers

Hypoactive sexual desire disorder (HSDD) means low or absent sexual desire that causes real distress or strain, rather than simply less interest than before. Vyleesi's approval is limited to premenopausal women whose HSDD is acquired (it wasn't always there) and generalized (it isn't tied to one partner or situation), and isn't better explained by a medical or psychiatric condition, relationship problems or a medication.

The label states it isn't indicated for postmenopausal women, for men, or to enhance performance. That's because the evidence submitted to FDA came from premenopausal women; it isn't a claim that the drug is known to fail in others.

Distress is central to the diagnosis. If lower desire doesn't bother you or strain your relationship, it isn't considered a disorder, and no treatment is needed.

If you are unsure whether your situation fits, that is a question for the assessment, not something you need to settle alone.

What the trials found

Two 24-week randomized trials compared bremelanotide with placebo. Women used it as needed, at least 45 minutes before anticipated sexual activity. Both trials measured desire on a validated questionnaire and distress about low desire on another.

On average, desire scores improved a little more with bremelanotide than placebo (for example, about 0.5 to 0.6 points versus 0.2 on the desire scale), and distress dropped a little more (about 0.7 versus 0.4). Those differences were statistically significant but modest. The number of satisfying sexual events didn't differ meaningfully from placebo. In plain terms, some women noticed a clear change, many didn't, and there's no test that predicts who will respond.

It's also worth remembering that placebo groups improved too. Some of the benefit people feel from any desire treatment comes from attention to the problem, conversation with a partner and the expectation of change.

The side effects that shape the decision

• Nausea in about 40% of users, usually easing after the first dose; 8% stopped because of it.
• Flushing in about 20% and headache in about 11%, plus injection-site reactions.
• A small, temporary rise in blood pressure and dip in heart rate after each dose. It's contraindicated with uncontrolled high blood pressure or known cardiovascular disease.
• Focal darkening of the skin on the face, gums or breasts in about 1%, more likely with darker skin and daily dosing, and not always reversible.
• Not for use in pregnancy; effective contraception is advised.

Perimenopause and after menopause

Perimenopausal women fall into a gray zone: still premenopausal by definition, but with shifting hormones that may themselves be affecting desire, sleep and comfort. After menopause, bremelanotide is off-label.

For postmenopausal women with distressing low desire, the 2019 global consensus statement on testosterone in women concluded that testosterone, used at doses that keep levels in the premenopausal range, is the only hormonal treatment with solid evidence for this problem. The same statement recommends against compounded testosterone and against using a blood testosterone level to diagnose HSDD.

Options often worth trying first in midlife

In women in their 40s and 50s, low desire frequently has a contributor that can be treated directly. Clinicians typically work through these before, or alongside, a desire medication:

• Vaginal dryness or pain with sex, which local vaginal estrogen treats effectively for many women.
• Hot flashes, night sweats and poor sleep, which systemic hormone therapy may help if it's a good fit for you.
• Medications that lower desire, such as some antidepressants.
• Mood, stress, fatigue and relationship context.

Questions worth asking yourself first

Before choosing any desire treatment, it helps to get specific about what's changed. Clinicians often find these questions clarify the picture quickly:

• Has desire faded with every partner and situation, or mainly in one context?
• Is sex uncomfortable or painful, even occasionally?
• Did the change start around a new medication, a life event, or the onset of hot flashes and broken sleep?
• Is the issue mostly desire, or is arousal, lubrication or orgasm also harder?
• How much does it bother you, as opposed to a partner?

How HealifyMD approaches it

Your clinician will review your menopausal status, blood pressure, heart history, medications and the specific pattern of what's changed. If a medication makes sense, options may include hormone therapy for women (listed at $349 for the first month, including the evaluation and baseline labs, then $99/month) or the compounded Triple Action Blend containing tadalafil, oxytocin and PT-141 (listed from $149/month). Prices are confirmed at your eligibility review.

Compounded PT-141 is not FDA-approved, FDA doesn't verify its safety, effectiveness or quality, and it isn't equivalent to Vyleesi. Tadalafil use in women is also off-label.